Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study

作者：Marcia Cruz Correa, Rui-Hua Xu, Markus Moehler, Do‐Youn Oh, Ken Kato, David R. Spigel, Hendrik‐Tobias Arkenau, Josep Tabernero, Anastasia Zimina, Yuxian Bai, Jianhua Shi, Keun Wook Lee, Hidekazu Hirano, Lucjan Wyrwicz, Roberto Pazo-Cid, Hui Xu, Tao Sheng, Gisoo Barnes · 发表于：Current Medical Research and Opinion · 年份：2025 · DOI：10.1080/03007995.2025.2501588 · 被引用次数：5 · 研究领域：Gastric Cancer Management and Outcomes、Esophageal Cancer Research and Treatment、Cancer Immunotherapy and Biomarkers

OBJECTIVE: RATIONALE-305 (NCT03777657) demonstrated that tislelizumab plus chemotherapy statistically improved overall survival versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC). This analysis examined patient-reported outcomes (PROs) at final analysis. METHODS: Adults with previously untreated, unresectable, or metastatic GC/GEJC were randomized (1:1) to tislelizumab or placebo intravenously once every 3 weeks plus chemotherapy. PROs assessed health-related quality of life (HRQoL) using EORTC QLQ-C30 and EORTC QLQ-STO22. A mixed model for repeated measures was used for PRO endpoints at treatment cycles 4 and 6, and time to deterioration was analyzed. RESULTS: Tislelizumab arm had improved outcomes over placebo arm in least-squares (LS) mean change from baseline to cycle 6 for QLQ-C30 global health status/quality of life (GHS/QoL) (LS mean difference, 2.52 [95% CI: 0.29-4.74]), physical functioning (2.46 [0.49-4.43]), fatigue (-3.01 [-5.78 to -0.24]), and STO22 index score (-1.62 [-3.12 to -0.12]) as well as maintenance of upper gastrointestinal symptoms (-1.74 [-3.55-0.06]) and pain/discomfort (-1.88 [-4.03-0.27]). Patients receiving tislelizumab plus chemotherapy had a lower risk for deterioration of GHS/QoL (hazard ratio 0.77 [95% CI: 0.60-0.98]), physical functioning (0.72 [0.57-0.92]), STO22 index score (0.64 [0.45-0.92]), pain/discomfort (0.74 [0.58-0.96]), and upper gastrointest...